NSCLC Immunotherapy Response Evaluation

The study cohort of NSCLC patients was established by recruiting patients from Yonsei Cancer Center, Seoul, Korea. Eighteen patients were in the discovery cohort, whereas 56 were in the validation cohort. Each patient was administered either nivolumab or pembrolizumab. Patients were classified as responders if they showed partial response (PR) or stable disease (SD) for >6 months according to Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1^{20 (link)}. Patients who showed progressive disease (PD) or SD for ≤6 months were classified as non-responders by RECIST ver. 1.1^{21 (link)}. Computed tomography (CT) studies were independently read by radiologists. All tumor samples were obtained from patients before immunotherapy.

Free full text: Click here

Cho J.W., Hong M.H., Ha S.J., Kim Y.J., Cho B.C., Lee I, & Kim H.R. (2020). Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer. Experimental & Molecular Medicine, 52(9), 1550-1563.

Publication 2020

Cancer Computed tomography Disease 6 Immunotherapy Nivolumab Nsclc Patients Pembrolizumab Radiologists Tumor

Corresponding Organization : Yonsei University

Top 5 similar protocols

Protocol cited in 6 other protocols

Variable analysis

independent variables

Type of immunotherapy (nivolumab or pembrolizumab)

dependent variables

Response to immunotherapy (partial response, stable disease, progressive disease)

control variables

Patients were recruited from the same institution (Yonsei Cancer Center, Seoul, Korea)
All tumor samples were obtained from patients before immunotherapy

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!